Erasca (ERAS) Liabilities and Shareholders Equity (2020 - 2026)
Erasca (ERAS) posted Liabilities and Shareholders Equity of $461.2 million for Q1 2026, up 16.43% on a QoQ basis from $396.2 million in Q4 2025, and down 2.12% year-over-year from $471.2 million in Q1 2025.
Erasca (ERAS) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Erasca's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $461.2 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 2.12% year-over-year to $461.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 15.05% YoY) and the FY2025 annual result came in at $396.2 million, down 21.17% from the prior year.
- Liabilities and Shareholders Equity was $461.2 million for Q1 2026 at Erasca, up from $396.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $528.9 million in Q3 2024 and bottomed at $370.0 million in Q1 2024.
- A 5-year average of $454.5 million and a median of $446.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 111.43% — and 2023, when it slipped 23.23%.
- Erasca's Liabilities and Shareholders Equity stood at $514.9 million in 2022, then declined by 23.23% to $395.3 million in 2023, then increased by 27.13% to $502.5 million in 2024, then dropped by 21.17% to $396.2 million in 2025, then gained by 16.43% to $461.2 million in 2026.
- Business Quant data shows ERAS's Liabilities and Shareholders Equity at $461.2 million in Q1 2026, $396.2 million in Q4 2025, and $420.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 461.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 461.23 Mn |
| Dec 31, 2025 | 396.15 Mn |
| Sep 30, 2025 | 420.40 Mn |
| Jun 30, 2025 | 445.39 Mn |
| Mar 31, 2025 | 471.24 Mn |
| Dec 31, 2024 | 502.53 Mn |
| Sep 30, 2024 | 528.90 Mn |
| Jun 30, 2024 | 525.74 Mn |
| Mar 31, 2024 | 370.02 Mn |
| Dec 31, 2023 | 395.30 Mn |
| Sep 30, 2023 | 419.41 Mn |
| Jun 30, 2023 | 440.66 Mn |
| Mar 31, 2023 | 467.54 Mn |
| Dec 31, 2022 | 514.91 Mn |
| Sep 30, 2022 | 446.43 Mn |
| Jun 30, 2022 | 444.82 Mn |
| Mar 31, 2022 | 475.47 Mn |
| Dec 31, 2021 | 501.42 Mn |
| Sep 30, 2021 | 521.95 Mn |
| Jun 30, 2021 | 210.38 Mn |